Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

First-Line Nivolumab Plus Ipilimumab or Cabozantinib Followed by Second-Line Lenvatinib Plus Everolimus in Metastatic TFE-Rearranged Renal Cell Carcinoma

ClinicalTrials.gov ID: NCT07947277

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07947277. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase 2 Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Cabozantinib as First-line Therapy, With Protocol-specified Lenvatinib Plus Everolimus in the Second-line, in Metastatic TFE-rearranged Renal Cell Carcinoma.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This randomized phase 2 study evaluates the efficacy and safety of nivolumab plus ipilimumab versus nivolumab plus cabozantinib as first-line treatment in patients with metastatic TFE-rearranged renal cell carcinoma. Patients are randomly assigned to one of the two treatment groups. Following disease progression, patients receive protocol-specified second-line treatment with lenvatinib plus everolimus. The study assesses treatment outcomes during first-line therapy and across the planned treatment sequence.

Study identification

NCT ID
NCT07947277
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
12 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 5, 2024 (Actual)
Primary completion
Oct 12, 2026 (Actual)
Completion
Nov 12, 2026 (Actual)
Last update posted
Nov 18, 2026

2024 – 2026

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
BUCARE New York New York 10032 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07947277, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 18, 2026 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.